What You Should Know:
– Neurogen Biomarking announced a strategic partnership with NeuroX, a venture of American TelePhysicians, to integrate virtual neurology services into Neurogen’s innovative brain health care ecosystem. The collaboration aims to…
Continue Reading
Characterizing subtle cognitive changes in preclinical Alzheimer’s disease (AD) is difficult using traditional neuropsychological assessments. Remote and unsupervised digital assessments can improve scalability, measurement reliability, and ecological validity, enabling the capture of subtle changes….
Continue Reading
Optical coherence tomography (OCT) is an efficient tool for non-invasively evaluating retinal structures. Retinal thinning changes assessed using OCT are recognized as potential biomarkers for systemic conditions such as Alzheimer’s disease, Parkinson’s disease, and…
Continue Reading
AI and digital technologies are critical to addressing the ever-expanding burden of dementia, write Professor Dag Aarsland and Dr Antonio Ruiz-Gonzalez
Dementia, caused by Alzheimer’s disease in most cases, is a growing crisis for the…
Chuck Papageorgiou, the CEO of NeuroEM Therapeutics, a Tampa-based biotech medical device company dedicated to advancing Alzheimer’s treatment joins eHealth Radio and the Alzheimer’s and Health News Channels.
Listen to interview with host Eric Michaels…
Continue Reading
Revolutionary Non-Invasive Treatment Shows Promise
Recent clinical findings presented at the Korean Society of Brain Neuromodulation Therapy Winter Conference reveal groundbreaking advancements in treating normal pressure hydrocephalus (NPH) through ultrasound technology. Professor Kim Jae-ho from…
The government has announced £82.6 million in research funding to support UK companies tackling cancer and accelerating drug discovery using AI.
Three projects will benefit from this support, two of which will use AI to…
Baljean Dhillon, professor of clinical ophthalmology at the University of Edinburgh (Credit: andrewperry.co.uk)
Researchers are working with high street opticians to develop a digital tool that can predict a person’s risk of dementia from…
Continue Reading
What You Should Know:
– Lantheus Holdings, Inc. (NASDAQ: LNTH), a leading radiopharmaceutical company, announced a definitive agreement to acquire Life Molecular Imaging Ltd. for $350M upfront and up to an additional $400M in potential…
Continue Reading
Remote, digital cognitive testing on an individual’s own device provides the opportunity to deploy previously understudied but promising cognitive paradigms in preclinical Alzheimer’s disease (AD). The Boston Remote Assessment for NeuroCognitive Health (BRANCH) captures…
Continue Reading
